CRISPR Tx Drug Targeting CD70 Offers Early Hope for Difficult T Cell Lymphomas

This weekend, CRISPR Therapeutics shared positive initial data from the Phase I COBALT-LYM trial of CTX130, an allogeneic CAR-T cell therapy, which demonstrated safety and efficacy when used to target solid tumors and certain hematological malignancies expressing CD70.